PRSS22 and invasive breast carcinoma: The results showed that PRSS22 was upregulated in breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), rectum adenocarcinoma (READ), uterine corpus endometrial carcinoma (UCEC), and thyroid carcinoma (THCA), while it was downregulated in kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), and liver hepatocellular carcinoma (LIHC).